B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $19
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $18 to $19.
B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $18 to $19.
